linjc16/ctgov huggingface dataset:
Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Study Overview
=================
Brief Summary
-----------------
A randomized controlled study to compare the efficacy of mirabegron, solifenacin and propevirine for treatment of Lower urinary tract symptoms during intravesical BCG installation

Official Title
-----------------
Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation: Prospective Randomized Controlled Trial

Conditions
-----------------
Voiding Disorders

Intervention / Treatment
-----------------
* Drug: Mirabegron, Propevirine, Solifenacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than age 18 years. Able to provide an informed consent. Denovo or recurrent cases with intermediate and high risk NMIBC eligible for intravesical BCG immunotherapy. Persistent LUTS after intravesical BCG induction. Exclusion Criteria: International Prostate symptom score (IPSS) greater than 20. Post-void residual (PVR) volume greater than 50 ml. Use of medications for overactive bladder. Pelvic surgery within the previous 6 months. Hypersensitivity for BCG or any of the above mentioned drugs. Tumor recurrence during follow up period. Other medical conditions that would be adversely affected by anticholinergics such as history of urinary retention due to BPH(Benign prostatic hyperplasia), constipation and history of narrow angle glaucoma.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Mirabegron arm<br>50 mg PO once daily | Drug: Mirabegron, Propevirine, Solifenacin<br>* Efficacy comparison<br>|
| Active Comparator: Propevirine arm<br>15 mg PO twice daily | Drug: Mirabegron, Propevirine, Solifenacin<br>* Efficacy comparison<br>|
| Active Comparator: Solifenacin arm<br>10 mg PO once daily | Drug: Mirabegron, Propevirine, Solifenacin<br>* Efficacy comparison<br>|
| Placebo Comparator: Placebo arm<br>starch tablet once daily | Drug: Mirabegron, Propevirine, Solifenacin<br>* Efficacy comparison<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dysuria | Compare the percentage of reduction of dysuria as measured by Pain Visual Analouge Score at 3 month follow up after using propiverine, mirabegron and solifenacin versus placebo. | 3 months |
Prevalence of Psoriasis Alba in Psoriatic Patients

Study Overview
=================
Brief Summary
-----------------
Interdigital psoriasis (psoriasis alba) is atypical and rare form of psoriasis that is often missed as it is commonly mistaken for either dermatoses or fungal infection.In this study we observed and analyzed the prevalence of psoriasis interdigital of palms and soles and brought medical awareness to dermatologists and family doctors this rare form of psoriasis. Thus, you can help to avoid mistaken diagnosis and the start of correct treatment as soon as possible.

Detailed Description
-----------------
Hospitalized patients and outpatient clinic will be included in the study after receiving the signature of a inform consent.Patients groups : 100 patients with psoriasis,100 patients with atopic dermatitis and 100 healthy patients (control group).Patients with atopic dermatitis will be the secondary control group.Patients diagnosed with inflammatory condition of interdigital skin of the palms and soles will be checked by fungal microscopy test.If the fungal test is negative ,we need to prepare to a biopsy of the skin in this area .Following results of the skin biopsy conclusions can be shown about the prevalence of interdigital psoriasis in psoriatic patients enabling suitable treatment to be given to the patients.

Conditions
-----------------
Psoriasis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients above 18 years old ,hebrew speakers, patients with psoriasis vulgaris or atopic dermatitis without systemic treatment Exclusion Criteria: patients below 18 years old, pregnancy women, patients treated with systemic agents for psoriasis or atopic dermatitis(methotrexate,cyclosporin,neotigason)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 3<br>patients with psoriasis , patients with atopic dermatitis and healthy patients. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
interdigital psoriasis (psoriasis alba)
Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy

Study Overview
=================
Brief Summary
-----------------
Acute stress-induced (takotsubo) cardiomyopathy or broken heart syndrome presents like a heart attack, classically is triggered by intense emotional or physical stress and can have serious health consequences. In the current study the investigators wish to establish whether there is a genetic predisposition making certain people more susceptible to this condition. This could also have implications for their families.

Detailed Description
-----------------
Acute stress-induced (takotsubo) cardiomyopathy presents like a myocardial infarct, is triggered by intense emotional or physical stress, and can have catastrophic and potentially fatal consequences. Despite data linking takotsubo cardiomyopathy with conditions that have a recognized genetic predisposition (such as mental health and neurological problems), a systematic and comprehensive characterisation of the genetic-epidemiologic factors in takotsubo is lacking. The researchers propose to further investigate this disorder by collecting blood from probands and characterising the genotype of patients with takotsubo cardiomyopathy in a large scale, nationwide genome wide association study. The investigators will also archive DNA for identification of future candidate genetic variants. Ultimately, understanding the underlying predisposition of this poorly understood neuro-psycho-cardiac disorder is essential if we are to move this field forward.

Official Title
-----------------
Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy: The GENETIC Study

Conditions
-----------------
Takotsubo Cardiomyopathy

Intervention / Treatment
-----------------
* Genetic: Blood collection for genetic analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients who have been diagnosed with Takotsubo cardiomyopathy in Scotland between 2010 to date. Familial cases elsewhere in the world who would be willing to participate. Exclusion Criteria: Unwillingness to participate
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Interventional Model Description: Single group observational study.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Takotsubo Case Arm<br>A patient that has been diagnosed with Takotsubo Cardiomyopathy from 2010 onwards. | Genetic: Blood collection for genetic analysis<br>* Blood collection for genetic analysis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Genome Wide Association Study | Genome Wide Association Study to search for susceptibility variants | At baseline |
Retrospective Analysis in Quality of Care Measures in Pediatric Adenotonsillectomy Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to interrogate the Partners for Kids (PFK) and the pediatric health information (PHIS) databases in addition to our own perioperative Nationwide Children's data base to look at outcomes, resource utilization, and cost trends for adenotonsillectomy in the nationally versus locally. The investigators also want compare Nationwide Children's to other regional and national tertiary pediatric institutions.

Official Title
-----------------
Cost Savings From Non-pharmacological Interventions for Pediatric Patients Undergoing Diagnostic Imaging at Nationwide Children's Hospital

Conditions
-----------------
Adenotonsillectomy

Intervention / Treatment
-----------------
* Other: Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who undergone an adenotonsillectomy, tonsillectomy or adenoidectomy during the past 2 years (2013-2015) who have ICD-9 codes (International Classification of Diseases) in the databases Exclusion Criteria: Non-adenotonsillectomy patients
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Adenotonsillectomy<br>Measuring quality of care in patients undergoing adenotonsillectomy. | Other: Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database<br>* Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gather data from PHIS and contrast local databases (PFK versus Nationwide Children's) | The significance is to identify outcome measures, resource utilization, and cost of adenotonsillectomy nationally as well as locally. | after patient's discharge, an expected average between 6 months to 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Quality, hospital care, adenotonsillectomy
Study on Nutrition and Cardiovascular Risk in Spain.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the distribution, awareness and control of main cardiovascular risk factors in the Spanish population. The main study variables are: Lifestyles (tobacco, alcohol, nutrition, physical activity) Biological risk factors either well-established (blood lipids, glucose, insulin and blood pressure) or emergent (leptin, C-reactive protein and other markers of inflammation)

Detailed Description
-----------------
Data collection comprised 3 sequential stages: computer-assisted telephone interview to obtain information on lifestyle, knowledge and attitudes about cardiovascular disease risk factors, and the signs and symptoms of heart attack and stroke, subjective health, and morbidity; first homevisit, to collect blood and urine samples for analysis by a central laboratory; second home visit, to measure anthropometric variables and blood pressure and to administer a computer-assisted dietary history; data on functional limitations are also collected from participants aged 65 years and older.

Official Title
-----------------
Study on Nutrition and Cardiovascular Risk in Spain.

Conditions
-----------------
Cardiovascular Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-institutionalized Spanish resident 18 years and over Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cardiovascular Risk Factors Control |  | 2 years | 
| Health-related quality of life |  | 2 years | 
| Use of health care services |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cardiovascular risk factors, Nutritional assessment, Epidemiology
Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

Study Overview
=================
Brief Summary
-----------------
The cerebral amyloïd angiopathy ( AAC) is a disease characterized by deposits of beta-amyloid peptids in the walls of the arteries of young and average calibre of the brain and the leptomeninx. The incidence of the AAC increases strongly with the age and represents a major cause of spontaneous brain haemorrhage to people over 60. The main demonstration is the lobar brain haemorrhage, the other ones are bleedings under arachnoid cortical and microbleedings leading to cognitive decline. Anatomical studies reported the presence of cortical infarcts in patients having amyloïd deposits suggesting an association between asymptomatic cortical cerebral infarcts and AAC. However prevalence and meaning of these infarcts in patients having an AAC remain badly known because of studies on low number of patients and the rarity of radiological analyses of these infarcts .A better knowledge of these asymptomatic cortical infarcts would allow to dread better cognitive disorders(confusions) presented by these patients, and to develop preventive strategies. Besides, the risk factors of severity of the AAC are little studied.

Official Title
-----------------
Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid

Conditions
-----------------
Amyloid Angiopathy

Intervention / Treatment
-----------------
* Other: medical report consultation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age>55 hospitalized in CAEN hospital and Paris St Joseph Hospital between 1st january 2011 and 31 december 2015 for cerebral haemorrhage with MRI images diagnosing cerebral amyloid angiopathy. Exclusion Criteria: Insufficient MRI images quality without FLAI sequence, T2 GRE disease with same radiologic and clinical signs that cerebral amyloid angiopathy.

Ages Eligible for Study
-----------------
Minimum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patient with cerebral infarction and associated factors in a cohort of cerebral amyloid angiopathy patients |  | 1day |
Impact Evaluation of Different Micturition Modes on Patients With Medullar Injury of Quality of Life and Their Occupations

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to analysis the personal determination factors (age, sex, stage of injury, pain, urinary continence and durations of spinal cord injury) and environmental determination factors (need for medical devices, nurse care and adaptation of accommodations) which affect the quality of life and their occupations on patients with medullar injury.

Official Title
-----------------
Evaluation of Impact of Different Micturition Modes on Patients With Medullar Injury of Their Quality of Life and Their Occupations

Conditions
-----------------
Medullary Injury, Micturition Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult patients with spinal cord injury; Live at home or in long-term care facility definitively; Have one of the following urination modes: urine with indwelling catheter in place catheter in suprapubic area intermittent catheterization by urethra intermittent catheterization by incontinent cystostomy sphincterotomy incontinent stomia (Bricker) Exclusion Criteria:

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality of life by QUALIVEEN-30 | The questionnaire QUALIVEEN-30 will be used to evaluate the quality of life. It's a reliable tool specially for patients with medullar injury and recommended by the European Association of Urology as Guideline since 2008. The french version is validated. | at baseline | 
| Model of human occupation | Questionnaire MCREO (french version) will be used to evaluate patients in the occupational aspect. | at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Medullary Injury, Micturition modes, Quality of life, Human occupation
PRIME vs Usual Care for Clinical High Risk

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether specialty care is superior to usual care in the treatment of patients at clinical high risk for psychosis.

Detailed Description
-----------------
This study is a randomized clinical effectiveness trial for patients at clinical high risk for psychosis that compares two treatments: 1) specialty care delivered in a specialized clinical for patients at clinical high risk for psychosis versus 2) treatment as usual in the community.

Official Title
-----------------
Randomized Trial of Usual Care vs. Specialized, Phase-specific Care for Youth at Risk for Psychosis

Conditions
-----------------
Clinical High Risk Syndrome for Psychosis

Intervention / Treatment
-----------------
* Other: PRIME care
* Other: Usual care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must meet all of the following: Male or female between 12 and 30 years old. Understand and sign an informed consent (or assent for minors) document in English. Meet diagnostic criteria for prodromal syndrome as per COPS criteria. Exclusion Criteria: Subjects must not meet any of the following: Diagnosis of current or lifetime Axis I psychotic disorder, including mood disorder with psychotic symptoms. Impaired intellectual functioning (full-scale IQ<70). However, those with an IQ in the 65-69 range will not be excluded if they score >75 on the WRAT Reading. Past or current history of a clinically significant central nervous system disorder that may contribute to prodromal symptoms or confound their assessment. Alcohol or substance dependence in the past 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: PRIME care<br>Specialized care in the PRIME clinic | Other: PRIME care<br>* Specialist medication, cognitive behavior therapy, family-focused therapy<br>|
| Active Comparator: Usual care<br>Usual care in the community | Other: Usual care<br>* Medication and psychotherapy as available form community providers<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Global Assessment of Functioning |  | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Service utilization | hospitalizations and emergency room use | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
prodrome, cognitive behavioral therapy, family focused therapy
Observational Aspirin Use and CVD in the Physicians' Health Study

Study Overview
=================
Brief Summary
-----------------
To analyze existing data from the Physicians Health Study (PHS), a randomized primary prevention trial of low-dose aspirin and beta carotene conducted among 22,071 U.S. male physicians, to address questions concerning aspirin and cardiovascular (CV) disease that could not adequately be addressed during the randomized aspirin period.

Detailed Description
-----------------
DESIGN NARRATIVE: The aspirin component of the trial was terminated on January 25, 1988, due to a demonstrated benefit of aspirin on myocardial infarction. At that time, however, the number of strokes and CV deaths experienced by trial participants was inadequate to definitively evaluate these endpoints. The beta carotene component of the trial continued uninterrupted until its scheduled termination in December, 1996. During this period detailed information continued to be collected on post-trial aspirin use through annual questionnaires. As of October, 1995, the number of deaths, including cardiovascular deaths, had increased fourfold from that in the randomized period, and the number of strokes had increased 3.5 times. The investigators used data from both the randomized aspirin period and the observational period following the trial to assess the impact of aspirin use on cardiovascular and total mortality, and the long-term impact of aspirin use on subsequent stroke and MI. The methods included analyses of both randomized aspirin assignment and of time-varying aspirin use, as assessed on the annual questionnaires. Because of the potential for bias, the propensity for aspirin use, particularly during the observational period was taken into account. Analyses included use of proportional hazards models allowing for both time-varying effects of aspirin use and controlling for time-varying confounders, as well as more complex procedures using causal modeling. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Cardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial Infarction, Cerebrovascular Accident

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |